Guide

GLOW, KLOW and Wolverine: what is actually in the peptide blends

GLOW, KLOW and Wolverine are marketing names for vials holding three or four peptides at once. The individual ingredients have been studied, mostly in animals. The mixtures have not been studied at all.

Published September 19, 2026

This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.

Three names, four ingredients

GLOW, KLOW and Wolverine are not compounds. They are product names for vials that hold several peptides mixed together, sold mostly by research-chemical storefronts and by a few telehealth providers. The names come from sellers, not from chemistry or from any regulator, so there is no official formula behind any of them.

The recipes that recur across sellers, and that one provider publishing its own formulations lists explicitly, are these:

Read that table as a family rather than three separate products. Wolverine is the base, GLOW adds one ingredient and KLOW adds another. The K in KLOW is the KPV.

No study has tested the blends

This is the thing worth knowing before anything else. There is no published trial of GLOW, KLOW or Wolverine as mixtures. Not in people, not in animals. The literature contains work on the individual ingredients, and that work was done one substance at a time.

That matters more than it sounds. Combining substances is not addition. Two things given together can produce a larger effect, a smaller one, or a different one, and the interaction is the reason drug combinations are studied as combinations rather than inferred from their parts. For these blends that study has not been done, so the correct description of their combined effect is unknown, rather than absent or proven.

It also means that any dosing chart you find for a blend is a convention somebody wrote down, not a figure traceable to a study. Where a study administered one of the individual ingredients to a stated population, that amount appears on that compound's own page on this site, attributed to the study that used it.

What the research on each ingredient actually found

BPC-157

The most studied of the four and still almost entirely preclinical. Published work is dominated by rat models of tendon, muscle, gut and skin injury, with a small number of uncontrolled human pilot reports and trials that have only recently been registered. The full picture, with every citation, is on the BPC-157 profile.

TB-500 and thymosin beta-4

TB-500 is sold as a fragment related to thymosin beta-4, a naturally occurring peptide that binds actin and is described in reviews as having a role in cell migration and tissue repair after injury (Expert Opinion on Biological Therapy review, 2012). A European double-blind, placebo-controlled, dose-escalation study in patients with venous ulcers was described in 2007, enrolling patients across sites in Italy and Poland (Annals of the New York Academy of Sciences, 2007). That publication sets out the design of the study rather than reporting its outcome, so it establishes that the work was undertaken, not that it worked.

GHK-Cu

GHK is a three-amino-acid sequence that occurs naturally in human plasma, saliva and urine, and whose concentration falls with age; it is proposed to act as a complex with copper (BioMed Research International review, 2015). Reviews describe effects on collagen and proteoglycan synthesis and on the enzymes that remodel tissue, drawn largely from cell and tissue work rather than from trials in people (Journal of Biomaterials Science review, 2008). Most of the human use behind GHK-Cu is topical and cosmetic rather than injected.

KPV

KPV is the last three amino acids of alpha-melanocyte-stimulating hormone, lysine-proline-valine. Its anti-inflammatory behaviour has been examined in two mouse models of colitis, where uptake through the PepT1 di- and tripeptide transporter was identified as a route of action (Gastroenterology, 2008), and in a separate pair of murine inflammatory bowel disease models (Inflammatory Bowel Diseases, 2008). Both are mouse studies. The work sits in gut inflammation, which is some distance from what the blends are marketed for.

Why they are sold together

The commercial logic is straightforward. Each ingredient is associated in marketing with repair or appearance, so a vial holding several of them can be described as doing more than a vial holding one, at a higher price and with a memorable name. GLOW suggests skin, Wolverine suggests healing.

That logic is about positioning, not evidence. It is also the reason the blends are easier to buy than to research: the names exist in vendor catalogues and almost nowhere in the scientific literature, so searching for a blend returns sellers rather than studies.

Where they stand legally

None of GHK-Cu, KPV, BPC-157 or TB-500 is an approved medicine in the United States, so no mixture of them is either. Vials sold online are labelled for research use and not for human use. Separately, some telehealth providers offer compounded versions prescribed after a consultation, and whether a pharmacy may lawfully compound a given substance turns on FDA's bulk drug substance lists, which moved for several of these compounds in 2026.

The legality guide sets out the three categories and what the 2026 committee vote did and did not decide. Each compound page on this site carries its own dated regulatory block.

What to ask before buying one

• What exactly is in this vial, in milligrams of each ingredient, and is that on the label?
• Is there a lot-specific certificate of analysis, and does its lot number match this vial?
• Is this being sold as research material or prescribed by a licensed clinician after a consultation?
• What study is any suggested amount taken from, and which population did that study enrol?
• If the answer to the last one is a chart on a seller's website, what is it based on?

Common questions